<code id='9FB9F667CE'></code><style id='9FB9F667CE'></style>
    • <acronym id='9FB9F667CE'></acronym>
      <center id='9FB9F667CE'><center id='9FB9F667CE'><tfoot id='9FB9F667CE'></tfoot></center><abbr id='9FB9F667CE'><dir id='9FB9F667CE'><tfoot id='9FB9F667CE'></tfoot><noframes id='9FB9F667CE'>

    • <optgroup id='9FB9F667CE'><strike id='9FB9F667CE'><sup id='9FB9F667CE'></sup></strike><code id='9FB9F667CE'></code></optgroup>
        1. <b id='9FB9F667CE'><label id='9FB9F667CE'><select id='9FB9F667CE'><dt id='9FB9F667CE'><span id='9FB9F667CE'></span></dt></select></label></b><u id='9FB9F667CE'></u>
          <i id='9FB9F667CE'><strike id='9FB9F667CE'><tt id='9FB9F667CE'><pre id='9FB9F667CE'></pre></tt></strike></i>

          focus

          focus

          author:explore    Page View:8156
          People taking notes while sitting around a meeting table
          Adobe

          It makes sense in theory for hospitals and startups to strike deals. Not only would doctors get first dibs on new health care technologies, their organizations would see windfalls if those startups hit it big.

          In practice, it often doesn’t work out that way. Doctors and other clinicians have their own way of doing things, and they typically don’t take kindly to an administrator telling them to learn a new product, especially if the goal is financial gain.

          advertisement

          Several health system-venture capital arrangements have fallen victim to this dynamic — but VC firm General Catalyst said this week it will buy nonprofit Summa Health, anyway.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          George Santos makes 1st court appearance after pleading not guilty to 13 counts
          George Santos makes 1st court appearance after pleading not guilty to 13 counts

          1:57GeorgeSantosarrivesatfederalcourtJune30,2023,inCentralIslip,N.Y.JohnMinchillo/APRep.GeorgeSantos

          read more
          Antibody drugs appear effective. Now can we make enough of them?
          Antibody drugs appear effective. Now can we make enough of them?

          VincenzoRusso,aresearcheratRegeneron,workstoisolateviralDNAclonesofSARS-CoV-2.EricaYoonforSTATTheCov

          read more
          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more

          The Readout: Amylyx, Alumis, and Lundbeck drug updates

          AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo